CN104911068B - 一种曼地亚红豆杉保健酒及其制作方法 - Google Patents
一种曼地亚红豆杉保健酒及其制作方法 Download PDFInfo
- Publication number
- CN104911068B CN104911068B CN201510388339.8A CN201510388339A CN104911068B CN 104911068 B CN104911068 B CN 104911068B CN 201510388339 A CN201510388339 A CN 201510388339A CN 104911068 B CN104911068 B CN 104911068B
- Authority
- CN
- China
- Prior art keywords
- taxus
- media
- extract
- health liquor
- wine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001674343 Taxus x media Species 0.000 title claims abstract description 44
- 230000036541 health Effects 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 26
- 240000007594 Oryza sativa Species 0.000 claims abstract description 14
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 14
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 14
- 235000009566 rice Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 6
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 5
- 240000000249 Morus alba Species 0.000 claims abstract description 5
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 5
- 235000014443 Pyrus communis Nutrition 0.000 claims abstract description 5
- 240000000111 Saccharum officinarum Species 0.000 claims abstract description 5
- 235000007201 Saccharum officinarum Nutrition 0.000 claims abstract description 5
- 240000008042 Zea mays Species 0.000 claims abstract description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 5
- 235000005822 corn Nutrition 0.000 claims abstract description 5
- 210000000582 semen Anatomy 0.000 claims abstract description 5
- 235000014101 wine Nutrition 0.000 claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 24
- 230000000694 effects Effects 0.000 claims description 19
- 238000000855 fermentation Methods 0.000 claims description 18
- 230000004151 fermentation Effects 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 239000003208 petroleum Substances 0.000 claims description 16
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 238000001514 detection method Methods 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- 238000010828 elution Methods 0.000 claims description 8
- 239000000377 silicon dioxide Substances 0.000 claims description 8
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000012259 ether extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 3
- 239000012046 mixed solvent Substances 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 229930003944 flavone Natural products 0.000 abstract description 7
- 235000011949 flavones Nutrition 0.000 abstract description 7
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 abstract description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 abstract description 6
- 150000002212 flavone derivatives Chemical class 0.000 abstract description 6
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 abstract description 6
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 abstract description 6
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 abstract description 6
- 235000005493 rutin Nutrition 0.000 abstract description 6
- 229960004555 rutoside Drugs 0.000 abstract description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 abstract description 6
- 201000004624 Dermatitis Diseases 0.000 abstract description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 abstract description 5
- 208000024780 Urticaria Diseases 0.000 abstract description 5
- 206010021198 ichthyosis Diseases 0.000 abstract description 5
- 229910052711 selenium Inorganic materials 0.000 abstract description 5
- 239000011669 selenium Substances 0.000 abstract description 5
- 239000011573 trace mineral Substances 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 235000013619 trace mineral Nutrition 0.000 abstract 1
- 241001149649 Taxus wallichiana var. chinensis Species 0.000 description 16
- 239000012071 phase Substances 0.000 description 12
- 241001116500 Taxus Species 0.000 description 11
- 235000013399 edible fruits Nutrition 0.000 description 11
- 230000001093 anti-cancer Effects 0.000 description 10
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 244000050510 Cunninghamia lanceolata Species 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 240000001417 Vigna umbellata Species 0.000 description 4
- 235000011453 Vigna umbellata Nutrition 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 244000162450 Taxus cuspidata Species 0.000 description 3
- 235000013334 alcoholic beverage Nutrition 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010025 steaming Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 235000020097 white wine Nutrition 0.000 description 3
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 2
- HXWZQRICWSADMH-SEHXZECUSA-N 20-hydroxyecdysone Natural products CC(C)(C)CC[C@@H](O)[C@@](C)(O)[C@H]1CC[C@@]2(O)C3=CC(=O)[C@@H]4C[C@@H](O)[C@@H](O)C[C@]4(C)[C@H]3CC[C@]12C HXWZQRICWSADMH-SEHXZECUSA-N 0.000 description 2
- DCEFCUHVANGEOE-UHFFFAOYSA-N Ecdysterone Natural products CC(CC(C)(C)O)C(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C DCEFCUHVANGEOE-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- NKDFYOWSKOHCCO-UHFFFAOYSA-N beta-ecdysone Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CCC(C)(O)C)CCC33O)C)C3=CC(=O)C21 NKDFYOWSKOHCCO-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 235000019990 fruit wine Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- YCXRBCHEOFVYEN-UHFFFAOYSA-N sciadopitysin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C(C=3C(=CC=C(C=3)C=3OC4=CC(OC)=CC(O)=C4C(=O)C=3)OC)=C2O1 YCXRBCHEOFVYEN-UHFFFAOYSA-N 0.000 description 2
- 235000015096 spirit Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 description 2
- 229930189271 taxine Natural products 0.000 description 2
- BAYHEZUZRPMUDM-RZHPVIQDSA-N taxinine Chemical compound O([C@H]1CC[C@@]2(C)[C@@H](OC(C)=O)[C@H](OC(C)=O)C3=C(C)C(=O)C[C@H](C3(C)C)[C@H]([C@@H]2C1=C)OC(=O)C)C(=O)\C=C\C1=CC=CC=C1 BAYHEZUZRPMUDM-RZHPVIQDSA-N 0.000 description 2
- SKJSIVQEPKBFTJ-HUWILPJBSA-N taxusin Chemical compound C1[C@@H](C2(C)C)C[C@H](OC(C)=O)C(C)=C2[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@]2(C)CC[C@H](OC(=O)C)C(=C)[C@@H]12 SKJSIVQEPKBFTJ-HUWILPJBSA-N 0.000 description 2
- DSCFFEYYQKSRSV-FEPQRWDDSA-N (-)-Quebrachitol Natural products COC1[C@@H](O)[C@@H](O)C(O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-FEPQRWDDSA-N 0.000 description 1
- DSCFFEYYQKSRSV-GWJPIIGYSA-N 1D-5-O-methyl-myo-inositol Chemical compound CO[C@@H]1[C@@H](O)[C@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-GWJPIIGYSA-N 0.000 description 1
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000019926 Keshan disease Diseases 0.000 description 1
- 229930190912 Makisterone Natural products 0.000 description 1
- YXPVYQIMXPYFSF-UHFFFAOYSA-N Makisterone A Natural products CC(C)C(C)(O)CC(O)C(C)(O)C1CCC2(O)C3=CC(=O)C4CC(O)C(O)CC4(C)C3CCC12C YXPVYQIMXPYFSF-UHFFFAOYSA-N 0.000 description 1
- CIQDSODCPIIBBH-UHFFFAOYSA-N Makisterone C Natural products C1C(O)C(O)CC2(C)C(CCC3(C(C(C)(O)C(O)CC(CC)C(C)(C)O)CCC33O)C)C3=CC(=O)C21 CIQDSODCPIIBBH-UHFFFAOYSA-N 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 235000016408 Podocarpus macrophyllus Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001116495 Taxaceae Species 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 235000009065 Taxus cuspidata Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 150000002686 makisterones Chemical class 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000002456 taxol group Chemical group 0.000 description 1
- VXQYICLHHMETFH-UHFFFAOYSA-N tetra-O-methylamentoflavone Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(OC)=CC(O)=C4C(=O)C=3)OC)=C2O1 VXQYICLHHMETFH-UHFFFAOYSA-N 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12G—WINE; PREPARATION THEREOF; ALCOHOLIC BEVERAGES; PREPARATION OF ALCOHOLIC BEVERAGES NOT PROVIDED FOR IN SUBCLASSES C12C OR C12H
- C12G3/00—Preparation of other alcoholic beverages
- C12G3/02—Preparation of other alcoholic beverages by fermentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种曼地亚红豆杉保健酒及其制作方法,其各组份原料的重量配比如下:糯米1000‑1200、大米150‑200、薏米50‑60、甘蔗叶10‑12、桑叶10‑12、玉米须10‑12、金银花10‑12、梨花10‑12、酒曲5‑15、水1500‑1800、曼地亚红豆杉提取物10‑15份。本发明的保健酒含有较高含量的总黄酮(以芦丁计),并且含有多种人体所必须的氨基酸以及微量元素硒。每次饮量可多可少并可长期饮用,特别是常饮可强身健体,延年益寿。男女老少均可饮用。本发明的保健酒对皮炎、荨麻疹、鱼鳞病等皮肤疾病具有良好治疗效果。
Description
技术领域
本发明涉及一种果酒及其制作方法,尤其是一种曼地亚曼地亚红豆杉保健酒及其制作方法。
背景技术
曼地亚红豆杉(Taxus media),属红豆杉科红豆杉属,是一天然杂交种,其母本为东北红豆杉(T.cuspidata),其父本为欧洲红豆杉(T.baccata),灌木,四季常青,主根不明显,侧根发达,叶枝茂盛,萌发力强,耐修剪,耐寒,可在多种气候、土壤条件下生长。国内自1996年始从加拿大引种栽培。曼地亚红豆杉与传统红豆杉相比,结构差异较大,但前者性能更为优异。红豆杉中提取的紫杉醇,是“目前唯一能遏制癌细胞生长的植物药”,被人们称为“黄金树”,成为世界上最昂贵的药用树种。当今世界野生红豆杉资源奇缺,它的树皮、树根、树叶、茎中都可提取具较高抗癌活性的二萜类化合物,可治疗多种病症,种子可榨油,叶可通经脉、降血压,并对治疗糖尿病及心脑血管疾病有明显效果。既是珍贵的药用树种,也是生态防护林工程建设首选树种之一。
红豆杉入药历史久远,在我国的《本草纲目》、《中药大辞典》、《东北药植志》、《吉林中草药》、《本草推陈》等医药书籍中有记载。入药可利尿、通经。对防治肿瘤、癌症、白血病、糖尿病有特殊的功效。目前利用红豆杉枝叶、根、皮在白酒内浸泡,制成的红豆杉酒已经很多。但是,通过白酒浸泡的方式只能将枝叶、根、皮中的脂溶性紫杉碱类和部分水溶性物质溶入酒中。红豆杉枝叶、根、皮中含有紫杉素(taxinine)A、H、K、L,尖叶土杉甾醇(ponasterol)A,脱皮甾酮(ecdysterone),金松双黄酮(soi-adopitysin),紫杉碱、紫杉醇、罗汉松甾酮等。这些化学成份有很好的防癌抗癌的药理作用,但是毒性较大,直接利用红豆杉枝叶、皮、根、泡酒后被溶入乙醇中,再被饮用是不恰当并对人体会产生危害作用。2002年,***禁止将红豆杉直接作为保健品和食品原料,使用枝叶、根、皮入药。人误食红豆杉的中毒表现主要为头昏、瞳孔放大、恶心、呕吐、弥散性腹痛、肌无力等,严重者出现心动缓慢、心脏骤停或死亡,病理检查出现肺水肿、心肌出血和心肌炎等改变。红豆杉直接泡水喝没有抗癌、防癌功效,因红豆杉抗癌、防癌的主要成分是紫杉醇,而紫杉醇不溶于水,即使用特殊的溶剂萃取,也必须添加助溶剂。有的人感冒发热时,也会撷取红豆杉枝叶煲水饮用,试图治病,这种做法是错误的。目前红豆杉的医疗用途主要体现于从树皮、根部、枝叶中提取紫杉醇制作抗癌类药物。直接服食红豆杉并无明显医疗效果,含红豆杉的食品、药品毒性较大,长期大量食用后可能产生严重的不良反应,甚至会导致死亡。
另外,中国专利申请96113169.1所公开的一种红豆杉珍果酒,是将红豆杉果实直接浸泡在白酒中制得的。这种方式,也只能将红豆杉果实中的部分水溶性或部分醇溶性物质溶入酒中,而不能充分利用果实中的其它营养成分。同时,这种方式制成的白酒酒精含量也高,不适宜作为保健用酒使用。中国专利申请200410054388.X所公开的一种曼地亚红豆杉保健酒及其制作工艺,其配方采用的是红豆杉果实,果实中还有种子,加工后味苦,影响成酒的口味。另外由于工艺不一样,酒中所含成份也不一样,它的工艺要经蒸制,其挥发性成份如红花油等可提取出来,但其它许多不挥发的有效成份丢失,同时由于蒸制时温度高,有些成份如10一D A B,红杉醇等成份遇高温而破坏。因此其工艺不合理。另外,其工艺是将糯米、红豆杉果实、橡子果实蒸熟冲打成糕,破碎,再拌入红花进行蒸制,再加入酒曲后又打成糕,再进行发酵,取酒酿经蒸馏制得成酒,并加入香料。该工艺复杂,流程很长。红豆杉果实蒸制多遍后再拿去发酵,红豆杉果实中的很多营养成份已经降价破坏流失。另外,该酒实际是一种蒸馏白酒,主要成份是乙醇,酒中含有的红豆杉果实中的营养成份极少,不能充分利用红豆杉果实中的营养成份。现今对红豆杉科的药用活性研究多集中在与紫杉醇结构类似的紫杉烷类化合物的抗癌活性方面,但对其他活性成分,如黄酮、多糖的研究较少。而黄酮与多糖具有广泛的药理作用,如作为免疫调节剂,能激活巨噬细胞、T淋巴细胞、LAK细胞等多种免疫细胞,促进细胞因子生成,活化补体;也有抗肿瘤、抗病毒、抗感染、抗消化性溃疡、抗氧化、降血糖、降血脂等多种活性,而且毒性较低。
发明内容
本发明针对上述现有技术的缺点,提供一种没有毒性,又能将红豆杉中对人体有益的成份充分地保留的保健酒,利用红豆杉叶枝释放的大量芳香烃与生物酮、青花素和微量元素等,形成在人体中活性极强、生物利用价值极高的有效挥发成份(即有效因子),这些有效因子进入血液循环,发挥其生物效应,如改善睡眠、降血压、保护心血管、抗衰老、增强机体免疫力、防癌保健,并通过发酵产生杂多糖达到营养保健的功能齐全的曼地亚红豆杉保健酒及其制作方法。特别需要指出的是,经过检测本保健酒中含有较高含量的总黄酮(以芦丁计),并且含有多种人体所必须的氨基酸以及业内公认的抗癌元素-微量元素硒。
为了达到上述目的,本发明解决其技术问题采用的技术方案是:一种曼地亚红豆杉保健酒,其各组份原料的重量配比如下:
糯米1000-1200、大米150-200、薏米50-60、甘蔗叶10-12、桑叶10-12、玉米须10-12、金银花10-12、梨花10-12、酒曲5-15、水1500-1800、曼地亚红豆杉提取物10-15份。
上述配方中,糯米为生态农业绿色粮食,曼地亚红豆杉提取物采用下述方法提取获得,水为优质泉水,其余几种添加材料可以起到清热祛火、滋阴润肺等功效。这几种原料配比发酵,可以达到我们确定的提高机体免疫力保健的目的,这种配方和工艺生产的酒没有任何副作用。
这种上述曼地亚红豆杉保健酒的制作方法,包括如下步骤:
(1)、获得曼地亚红豆杉活性提取物:将曼地亚红豆杉枝叶混合粉碎后,取药粉适量,加入石油醚中30-38℃浸泡1小时,重复进行该步骤3次,分离石油醚和固体粉末;将得到的石油醚提取液蒸干,粉末进行柱色谱分离,使用二氧化硅和十八烷基硅烷键合硅胶为填充剂,以pH值为5.5-6.5的稀醋酸溶液为流动相A,以乙醇∶石油醚∶氯仿=15∶1∶1的混合溶剂为流动相B,梯度洗脱,柱温为20-30℃,流速为1.5-2.0ml/min,检测波长为220nm,用HPLC分析,提取出所需曼地亚红豆杉活性成分;
所述梯度洗脱条件为
时间/分钟 | 流动相/B%(ml) | 流动相/A%(ml) |
0 | 90-95 | 5-10 |
5 | 80-85 | 15-20 |
20 | 72-75 | 25-28 |
35 | 65-70 | 30-35 |
50 | 80-85 | 15-20 |
(2)、将除曼地亚红豆杉提取物、酒曲以外的上述配方组分加水蒸熟,放凉后,拌入酒曲,放入容器中密封发酵;
(3)、密封发酵3-4天后,加入曼地亚红豆杉提取物,搅匀、发酵;
(4)、再在0-30℃下继续密封发酵20天-1个月后,加入食用级柠檬酸,调PH值为6.5-6.8,继续发酵;
(5)、再继续在常温密封发酵20天-1个月后,加入食用级柠檬酸,调PH值为7.0-7.3,继续发酵;
(6)、15-20天后,调酒液PH值为中性,压榨得酒液,再经过精滤即得。
附图说明:
图1表示实施例1得到的红豆杉酒的高效液相色谱图;
图2表示实施例2得到的红豆杉酒的高效液相色谱图。
经检测数据表明,采用上述配方和工艺,曼地亚红豆杉提取物(未经蒸制)、糯米、酒曲经发酵,得到的保健酒中最大程度地保留了对人体有益的成分,并且祛除了毒性成分,对人体安全无害。且本保健酒中含有较高含量的总黄酮(以芦丁计),并且含有多种人体所必须的氨基酸以及业内公认的抗癌元素-微量元素硒。
具体实施方式
下面通过实施例对本发明的方案作进一步描述:
实施例1:一种曼地亚红豆杉保健酒,其各组份原料的重量配比如下:
糯米1000、大米160、薏米50、甘蔗叶10、桑叶12、玉米须12、金银花12、梨花10-12、酒曲10、水1800、曼地亚红豆杉提取物12份。
这种上述曼地亚红豆杉保健酒的制作方法,包括如下步骤:
(1)、获得曼地亚红豆杉活性提取物:将曼地亚红豆杉枝叶混合粉碎后,取药粉适量,加入石油醚中35℃浸泡1小时,重复进行该步骤3次,分离石油醚和固体粉术;将得到的石油醚提取液蒸干,粉末进行柱色谱分离,使用二氧化硅和十八烷基硅烷键合硅胶为填充剂,以pH值为6.0的稀醋酸溶液为流动相A,以乙醇∶石油醚∶氯仿=15∶1∶1的混合溶剂为流动相B,梯度洗脱,柱温为25℃,流速为1.5ml/min,检测波长为220nm,用HPLC分析,提取出所需曼地亚红豆杉活性成分;
所述梯度洗脱条件为
时间/分钟 | 流动相/B%(ml) | 流动相/A%(ml) |
0 | 95 | 5 |
5 | 80 | 20 |
20 | 75 | 25 |
35 | 65 | 35 |
50 | 80 | 20 |
(2)、将除曼地亚红豆杉提取物、酒曲以外的上述配方组分加水蒸熟,放凉后,拌入酒曲,放入容器中密封发酵;
(3)、常温密封发酵3天后,加入曼地亚红豆杉提取物,搅匀、发酵;
(4)、再继续在4℃下,密封发酵20天后,加入食用级柠檬酸,调PH值为6.5-6.8,继续发酵;
(5)、再继续在常温下,密封发酵20天后,加入食用级柠檬酸,调PH值为7.0-7.3,继续发酵;
(6)、20天后,调酒液PH值为中性,压榨得酒液,再经过精滤即得。
实施例2:一种曼地亚红豆杉保健酒,其各组份原料的重量配比如下:
糯米1200、大米200、薏米60、甘蔗叶12、桑叶10、玉米须12、金银花12、梨花12、酒曲15、水1500、曼地亚红豆杉提取物15份。
这种上述曼地亚红豆杉保健酒的制作方法,包括如下步骤:
(1)、获得曼地亚红豆杉活性提取物:将曼地亚红豆杉枝叶混合粉碎后,取药粉适量,加入石油醚中30℃浸泡1小时,重复进行该步骤3次,分离石油醚和固体粉术;将得到的石油醚提取液蒸干,粉末进行柱色谱分离,使用二氧化硅和十八烷基硅烷键合硅胶为填充剂,以pH值为6.0的稀醋酸溶液为流动相A,以乙醇∶石油醚∶氯仿=15∶1∶1的混合溶剂为流动相B,梯度洗脱,柱温为25℃,流速为1.5ml/min,检测波长为220nm,用HPLC分析,提取出所需曼地亚红豆杉活性成分;
所述梯度洗脱条件为
时间/分钟 | 流动相/B%(ml) | 流动相/A%(ml) |
0 | 90 | 10 |
5 | 85 | 15 |
20 | 72 | 28 |
35 | 70 | 30 |
50 | 80 | 20 |
(2)、将除曼地亚红豆杉提取物、酒曲以外的上述配方组分加水蒸熟,放凉后,拌入酒曲,放入容器中密封发酵;
(3)、常温密封发酵3天后,加入曼地亚红豆杉提取物,搅匀、发酵;
(4)、再继续在25℃下密封发酵1个月后,加入食用级柠檬酸,调PH值为6.5-6.8,继续发酵;
(5)、再继续在常温下,密封发酵1个月后,加入食用级柠檬酸,调PH值为7.0-7.3,继续发酵;
(6)、20天后,调酒液PH值为中性,压榨得酒液,再经过精滤即得。
检测实施例1、2所得到的保健酒的理化指标,参照GB2757-2012蒸馏酒及其配制酒、GB27588-2011露酒进行检测,检测结果如下:
理化指标符合GB2757-2012蒸馏酒及其配制酒、GB27588-2011露酒的规定。
同时,对本发明的保健酒中微量元素硒含量进行了测定,使用RF-540(分子荧光)仪,检测依据GB 5009.93-2010,检测环境为19℃,相对湿度70%。结果如下:
众所周知,补硒可有效预防克山病、大骨节病,冠心病等,可使肝癌发生率下降35%,可阻断乙肝病毒在人群中传播以及提高免疫力等功能。
检测实施例1、2的保健酒的总黄酮(以芦丁计)含量,使用Cary100Bio分光光度计,检测依据采用JY/T 022-1996紫外和可吸收光谱方法通则,检测环境为18℃,相对湿度60%。结果如下:
从上述检测结果中可以看出,本发明的保健酒中含有丰富的总黄酮,而以芦丁为代表的黄酮类物质具有抗炎、保持血管正常作用、抗病毒、抑制醛糖还原酶的功效,属于人体所必需物质,常饮本品可强身健体,延年益寿。男女老少均可饮用。
检测实施例1、2的保健酒的氨基酸含量,使用LC-20AT高效液相色谱仪,检测依据采用GB/T 16631-2008高效液相色谱法通则,检测环境为18℃,相对湿度78%。结果如下:
可见,本发明的保健酒中含有丰富含量的多种氨基酸,这些氨基酸成分可有效补充人体每日所必需的氨基酸。
此外本发明的保健酒通过对大鼠服用以及健康人群服用的长期观察,发现本发明的保健酒安全有效,无毒副作用。未发生大鼠死亡以及人服用后产生任何不适的现象。而且经临床试验研究发现,本发明的保健酒对皮炎、荨麻疹、鱼鳞病等皮肤疾病具有治疗效果。
实施例1~2对皮炎的试验效果
上表数据说明饮用实施例1~2的本发明产品对皮炎具有较好的效果,其中实施例1的效果最好。
实施例1~2对荨麻疹的试验效果
上表数据说明饮用实施例1~2的本发明产品对荨麻疹具有较好的效果,其中实施例2的效果最好。
实施例1~2对鱼鳞病的试验效果
上表数据说明饮用实施例1~2的本发明产品对鱼鳞病具有较好的效果,其中实施例2的效果最好。
本发明进一步考察保健酒的免疫保健功能。分别将300名年龄分布在18-60岁的人群平均随机分为两组,一组每天规律服用本发明的保健酒1-2次,每次50-100mL。一组作为对照组,不服用本发明的保健酒。每天正常作息饮食。两组人群均保持大致相同的作息饮食规律。在2014.11.01-2015.1.31的三个月时期内,分别统计两组人群的疾病发生情况。统计结果如下:两组人群在三个月考察期内均存活,其中服用本发明的保健酒的第一组人群中,出现感冒、发烧等轻微症状9例,无恶性肿瘤及其他重大疾病发生。第二组人群中,出现感冒、发烧等症状28例,其中7例转化为肺炎住院治疗,出现冠心病、心脏病、脑血管疾病住院治疗病例8例。可见,本发明的保健酒确实具有免疫保健之功效。
本发明所提供的曼地亚红豆杉保健酒及其制作方法,由曼地亚红豆杉提取物发酵而成,能对人体产生互补和协同作用,其有益的效果是:1)制作工艺流程简单、产品指标符合国家标准。2)酒中最大程度地保留了对人体有益的成分,并且祛除了毒性成分,对人体安全无害。3)保健酒中含有较高含量的总黄酮(以芦丁计),并且含有多种人体所必须的氨基酸以及业内公认的抗癌元素-微量元素硒。每次饮量可多可少并可长期饮用,特别是常饮可强身健体,延年益寿。男女老少均可饮用。4)本发明的保健酒对皮炎、荨麻疹、鱼鳞病等皮肤疾病具有良好治疗效果。
Claims (1)
1.一种曼地亚红豆杉保健酒,其各组份原料的重量配比如下:
糯米1000-1200、大米150-200、薏米50-60、甘蔗叶10-12、桑叶10-12、玉米须10-12、金银花10-12、梨花10-12、酒曲5-15、水1500-1800、曼地亚红豆杉提取物10-15份,其中该曼地亚红豆杉保健酒的制作方法,包括如下步骤:
(1)、获得曼地亚红豆杉活性提取物;
(2)、将除曼地亚红豆杉提取物、酒曲以外的上述配方组分加水蒸熟,放凉后,拌入酒曲,放入容器中密封发酵;
(3)、密封发酵3-4天后,加入曼地亚红豆杉提取物,搅匀、发酵;
(4)、再在0-30℃下继续密封发酵20天-1个月后,加入食用级柠檬酸,调PH值为6.5-6.8,继续发酵;
(5)、再继续在常温密封发酵20天-1个月后,加入食用级柠檬酸,调PH值为7.0-7.3,继续发酵;
(6)、15-20天后,调酒液PH值为中性,压榨得酒液,再经过精滤即得;
其获得曼地亚红豆杉提取物的具体操作为:
将曼地亚红豆杉枝叶混合粉碎后,取药粉适量,加入石油醚中30-38℃浸泡1小时,重复进行该步骤3次,分离石油醚和固体粉末;将得到的石油醚提取液蒸干,粉末进行柱色谱分离,使用二氧化硅和十八烷基硅烷键合硅胶为填充剂,以pH值为5.5-6.5的稀醋酸溶液为流动相A,以乙醇∶石油醚∶氯仿=15∶1∶1的混合溶剂为流动相B,梯度洗脱,柱温为20-30℃,流速为1.5-2.0ml/min,检测波长为220nm,用HPLC分析,提取出所需曼地亚红豆杉活性成分;
所述梯度洗脱条件为:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510388339.8A CN104911068B (zh) | 2015-07-06 | 2015-07-06 | 一种曼地亚红豆杉保健酒及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510388339.8A CN104911068B (zh) | 2015-07-06 | 2015-07-06 | 一种曼地亚红豆杉保健酒及其制作方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104911068A CN104911068A (zh) | 2015-09-16 |
CN104911068B true CN104911068B (zh) | 2017-11-17 |
Family
ID=54080516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510388339.8A Expired - Fee Related CN104911068B (zh) | 2015-07-06 | 2015-07-06 | 一种曼地亚红豆杉保健酒及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104911068B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110423659A (zh) * | 2019-08-07 | 2019-11-08 | 陈中志 | 一种以红豆杉为主料的保健酒的制备方法及保健酒 |
CN113621467A (zh) * | 2021-07-02 | 2021-11-09 | 冯显华 | 一种曼地亚红豆杉酒及其制作方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1746285A (zh) * | 2004-09-06 | 2006-03-15 | 黄金福 | 红豆杉果酒 |
CN103191041A (zh) * | 2013-04-18 | 2013-07-10 | 江苏红豆杉药业有限公司 | 一种具有抗氧化作用的红豆杉枝叶提取物、其提取方法及应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000039284A (ko) * | 1998-12-12 | 2000-07-05 | 심규산 | 주류 제조방법 |
CN101875893B (zh) * | 2010-06-11 | 2012-07-25 | 杨波 | 一种红豆杉果酒及其制备方法 |
CN103211844B (zh) * | 2013-03-26 | 2015-04-15 | 安徽和华生物医药科技有限公司 | 红豆杉活性提取物的提取方法 |
-
2015
- 2015-07-06 CN CN201510388339.8A patent/CN104911068B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1746285A (zh) * | 2004-09-06 | 2006-03-15 | 黄金福 | 红豆杉果酒 |
CN103191041A (zh) * | 2013-04-18 | 2013-07-10 | 江苏红豆杉药业有限公司 | 一种具有抗氧化作用的红豆杉枝叶提取物、其提取方法及应用 |
Non-Patent Citations (1)
Title |
---|
红豆杉资源及开发利用综述;马明东,等;《四川林业科技》;20040331;第25卷(第1期);第21-25页 * |
Also Published As
Publication number | Publication date |
---|---|
CN104911068A (zh) | 2015-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wenli et al. | Health benefits of wolfberry (Gou Qi Zi, Fructus barbarum L.) on the basis of ancient Chineseherbalism and Western modern medicine | |
CN103230473B (zh) | 黑枸杞有效提取物、提取方法以及提取物应用 | |
CN103702675B (zh) | 具有增加含量的活性类黄酮化合物的漆树提取物及其制备方法 | |
Veljović et al. | Medicinal fungus Ganoderma lucidum as raw material for alcohol beverage production | |
CN101333203A (zh) | 落叶松中萃取二氢化槲皮素的方法 | |
Tisnadjaja et al. | Potency of cinnamomum burmannii as antioxidant and α glucosidase inhibitor and their relation to trans-cinamaldehyde and coumarin contents | |
Kandimalla et al. | A review on anti-diabetic potential of genus Solanum (Solanaceae) | |
CN104911068B (zh) | 一种曼地亚红豆杉保健酒及其制作方法 | |
CN101032564B (zh) | 调节血脂养生酒及其制备方法 | |
Kanoma et al. | Qualitative and quantitative phytochemical screening of cola nuts (Cola nitida and Cola acuminata) | |
CN101940580A (zh) | 调节血脂养生酒及其制备方法 | |
CN105733902B (zh) | 一种解酒型柳叶蜡梅葛根黄酒的制备方法 | |
CN104946460B (zh) | 一种曼地亚红豆杉奶味酒饮料及其制作方法 | |
CN101333204B (zh) | 落叶松中萃取二氢化槲皮素的制备方法 | |
KR20170015618A (ko) | 동충하초를 이용한 기능성 주류 및 그 제조방법 | |
CN105713787B (zh) | 一种护肝型藏红花葛根黄酒的制备方法 | |
Boonpisuttinant et al. | In vitro alpha-glucosidase and alpha-amylase enzyme-inhibited activities by water-lily (Nymphaea genus) extracts | |
CN110664876B (zh) | 一种大枣落果多酚类组分的提取方法 | |
KR20090092905A (ko) | 생약재 추출물을 함유하는 당뇨병 치료 및 예방용 약학조성물 | |
CN105076562B (zh) | 一种曼地亚红豆杉保健茶及其制作方法 | |
Setiawati et al. | Effect of sucrose as an elicitor in increasing quercetin-3-O-rhamnoside (quercitrin) content of chrysanthemum (Chrysanthemum morifolium Ramat) callus culture based on harvest time differences | |
Eshiet et al. | Herbal benefits of tea | |
CN101870944A (zh) | 一种调节血脂养生酒及其制备方法 | |
CN102199502B (zh) | 一种显著增加白藜芦醇含量的干红葡萄酒的制备方法 | |
WAPWERA | EXTRACTION AND ISOLATION OF ASCORBIC ACID (VITAMIN C) FROM AUSTRALIAN PINE (CASUARINA EQUISETIFOLIA) NEEDLES GROWN IN JOS AND ENVIRONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20171117 |